Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

VGX-3400

Vaccine (DNA plasmid) · Immune activation

Phase 1 Most advanced trial (none active)
1 Registered trials

What is VGX-3400?

VGX-3400 is a plasmid DNA vaccine delivered via intramuscular injection with electroporation. It is studied in healthy volunteers for influenza prevention.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine (DNA plasmid)
Mechanism
Immune activation
Therapy area
Infectious disease
In trials of
INO
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01184976 Phase 1 Healthy Completed INO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.